What's in Indivior Inc.'s pipeline?

Indivior Inc. has 29 drugs in our index: 9 marketed, 0 filed, 2 in Phase 3, 6 in Phase 2, 12 in Phase 1.

Which companies overlap with Indivior Inc.'s portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Orexo AB, New York State Psychiatric Institute, Carolinas Pain Institute, Friends Research Institute, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/indivior-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-09 · How we verify

Indivior Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Indivior Inc. pipeline: 9 marketed, 0 filed, 2 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 2 Phase 3 6 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Buprenorphine (Subutex)	Buprenorphine (Subutex)	marketed	Partial opioid agonist	Mu-opioid receptor (μ-OR)	Psychiatry / Addiction Medicine
Suboxone Sublingual Film	Suboxone Sublingual Film	marketed
PERSERIS	PERSERIS	marketed
Suboxone	Suboxone	marketed			Other
SL Buprenorphine	SL Buprenorphine	marketed
Zubsolv sublingual tablets	Zubsolv sublingual tablets	marketed	Opioid agonist-antagonist combination	Mu-opioid receptor (buprenorphine); opioid receptors (naloxone antagonism)	Psychiatry / Addiction Medicine
TM buprenorphine	TM buprenorphine	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (OPRM1)	Psychiatry / Addiction Medicine
Subutex, Buprenorphine Hydrochloride, SCH 28444	Subutex, Buprenorphine Hydrochloride, SCH 28444	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)	Psychiatry / Addiction Medicine
Transmucosal Buprenorphine	Transmucosal Buprenorphine	marketed	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)	Pain Management, Addiction Medicine
RBP-7000	RBP-7000	phase 3	Atypical antipsychotic, long-acting injectable	Dopamine D2 receptor	Psychiatry
RBP-6000	RBP-6000	phase 3	Opioid receptor partial agonist (long-acting depot)	Mu-opioid receptor (μ-OR)	Psychiatry / Substance Use Disorder

Therapeutic area mix

Psychiatry / Addiction Medicine · 4
Other · 3
Pain Management, Addiction Medicine · 1
Psychiatry · 1
Psychiatry / Substance Use Disorder · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 2 shared drug classes
Orexo AB · 2 shared drug classes
New York State Psychiatric Institute · 2 shared drug classes
Carolinas Pain Institute · 1 shared drug class
Friends Research Institute, Inc. · 1 shared drug class
Johns Hopkins University · 1 shared drug class
Fox Chase Cancer Center · 1 shared drug class
King's College London · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Indivior Inc.:

Cite this brief

Drug Landscape (2026). Indivior Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/indivior-inc. Accessed 2026-06-09.